HyQvia

HyQvia (human normal immunoglobulin 10% with recombinant human hyaluronidase) is a facilitated subcutaneous immunoglobulin (fSCIG) therapy. It is a dual-vial unit containing human normal immunoglobulin G (IgG) and recombinant human hyaluronidase (rHuPH20). The hyaluronidase component temporarily depolymerizes hyaluronan in the subcutaneous extracellular matrix, increasing tissue permeability and allowing for the subcutaneous infusion of large volumes of immunoglobulin. This enables up to once-monthly dosing, combining the convenience of subcutaneous administration with the less frequent dosing schedule of intravenous immunoglobulin (IVIG). HyQvia is approved for the treatment of primary immunodeficiency (PI) and as a maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability.

Brand names

HyQvia

Other names

fSCIGfSCIG 10%fSCIG 20%human normal immunoglobulin + recombinant human hyaluronidasehyaluronidase and immune globulinhyaluronidase-facilitated subcutaneous immunoglobulinIGHyIGHy10IGHy-10IGHy 10IGHy20IGHy-20IGHy 20immune globulin infusion 10% (human) with recombinant human hyaluronidaseimmune globulin subcutaneous (human), 20% solution and recombinant human hyaluronidasepH4 treated acid human globulin (subcutaneous injection) / vorhyaluronidase alfa (genetical recombination)